Increased pregnancy rates after ultralong postoperative therapy with gonadotropin- releasing hormone analogs in patients with endometriosis Dagmar Rickes,

Slides:

Advertisements

Similar presentations

Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice Michelle Nisolle, M.D., Ph.D., Françoise Casanas-Roux, B.S.,

Advertisements

Prediction of the effects of gonadotropin-releasing hormone agonist therapy in uterine leiomyoma by T1 contrast-enhanced magnetic resonance imaging sequences

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Antagonists in poor-responder patients

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis George Griesinger, M.D.,

Efficacy and tolerability of vaginal progesterone capsules (Utrogest™ 200) compared with progesterone gel (Crinone™ 8%) for luteal phase support during.

Does Previous Salpingectomy Improve Implantation and Pregnancy Rates in Patients with Severe Tubal Factor Infertility who are Undergoing In Vitro Fertilization?

Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation Renato.

Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women Daniel A Dumesic, M.D.,

Effect of chronic hypertension on assisted pregnancy outcomes: a population-based study in Ontario, Canada Natalie Dayan, M.D., Andrea Lanes, M.Sc.,

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Taylor P. Kohn, M. Phil. , Jaden R. Kohn, B. S. , Alexander W

No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.

Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage.

Marcos Meseguer, Ph. D. , Rebeca Santiso, Ph. D. , Nicolás Garrido, Ph

A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone.

Day 4 Estradiol Levels Predict Pregnancy Success in Women Undergoing Controlled Ovarian Hyperstimulation for IVF John Y Phelps, M.D., Adam S Levine,

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing.

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting Karl R Hansen, M.D., Ph.D., Jamie L Morris,

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Prolonged gonadotropin-releasing hormone agonist therapy reduced expression of nitric oxide synthase in the endometrium of women with endometriosis and.

Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5

Intracytoplasmic sperm injection in partial globozoospermia

Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy?

Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled,

Robert F. Casper, M.D. Fertility and Sterility

Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain Mohamed A. Bedaiwy,

Conversion of high-response gonadotropin intrauterine insemination cycles to in vitro fertilization results in excellent ongoing pregnancy rates Amy.

A comparison of three downregulation approaches for poor responders undergoing in vitro fertilization Laura Detti, M.D., Daniel B. Williams, M.D., Jared.

Initial IVF-ET experience with assisted hatching performed 3 days after retrieval followed by day 5 embryo transfer Margaret C. Graham, M.S., Kathleen.

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement Fertility and Sterility Volume 102,

Mark D Hornstein, M. D. , Owen K Davis, M. D. , Joe B Massey, M. D

How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis Dimitra Kyrou,

Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized.

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Thomas M. D’Hooghe, M. D. , Ph. D. , Bénédicte Denys, M. D

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Pia Saldeen, M. D. , Ph. D. , Ahmed M. Abou-Setta, M. D

Prediction of the effects of gonadotropin-releasing hormone agonist therapy in uterine leiomyoma by T1 contrast-enhanced magnetic resonance imaging sequences

Bruce S Shapiro, M. D. , Kevin S Richter, Ph. D. , Dee C Harris, M. T

Transient abdominal ovariopexy for adhesion prevention in patients who underwent surgery for severe pelvic endometriosis Jonathan Ouahba, M.D., Patrick.

Regulation of assisted reproductive technologies in the United States

Patrick Quinn, Ph.D. Fertility and Sterility

Hassan N Sallam, M.D., Ph.D., F.R.C.O.G., Sameh S Sadek, M.D.

Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist Annika.

Effect of endometriosis on in vitro fertilization

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Intestinal endometriosis complicated by ileal perforation after initiation of gonadotropin- releasing hormone agonist therapy Sayaka Saito, M.D., Takashi.

Fertility and Sterility

Spontaneous pregnancy in a patient who was homozygous for the Q106R mutation in the gonadotropin-releasing hormone receptor gene Didier Dewailly, M.D.,

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Comparison of the effectiveness of single intrauterine insemination (IUI) versus double IUI per cycle in infertile patients Saeed Alborzi, M.D., Shahdokht.

Luteal phase support Fertility and Sterility

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.

Soluble HLA-G in the peritoneal fluid of women with endometriosis

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization Ginny Mounce,

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Presentation transcript:

Increased pregnancy rates after ultralong postoperative therapy with gonadotropin- releasing hormone analogs in patients with endometriosis Dagmar Rickes, M.D., Ingrid Nickel, M.D., Siegfried Kropf, Ph.D., Jürgen Kleinstein, M.D. Fertility and Sterility Volume 78, Issue 4, Pages 757-762 (October 2002) DOI: 10.1016/S0015-0282(02)03338-1

FIGURE 1 Randomization of patients. Rickes. Ultralong GnRH-a therapy before ART. Fertil Steril 2002. Fertility and Sterility 2002 78, 757-762DOI: (10.1016/S0015-0282(02)03338-1)

FIGURE 2 Pregnancy rates at different stages of endometriosis. (A), Patients undergoing IUI. (B), Patients undergoing IVF or ICSI. ∗P<.05. Shaded bar = with GnRH-a; open bar = without GnRH-a. Rickes. Ultralong GnRH-a therapy before ART. Fertil Steril 2002. Fertility and Sterility 2002 78, 757-762DOI: (10.1016/S0015-0282(02)03338-1)